Core Points - The company has completed the cancellation of 524,300 stock options from the 2021 stock option incentive plan due to certain performance criteria not being met by some incentive recipients [2][3] - The cancellation was approved by the board of directors and aligns with the regulations set forth in the "Management Measures for Equity Incentives of Listed Companies" and the company's own incentive plan [3] - The cancellation will not significantly impact the company's financial status or operational results, nor will it affect the motivation and stability of the management team [3] Summary by Sections - Announcement of Cancellation: The company announced the cancellation of stock options for 31 incentive recipients who did not fully meet the performance assessment for 2024, resulting in a total of 524,300 options being canceled [2] - Regulatory Compliance: The cancellation process has been submitted to and confirmed by the Shenzhen branch of China Securities Depository and Clearing Co., Ltd., ensuring compliance with relevant regulations [3] - Impact Assessment: The company asserts that this cancellation will not disrupt the ongoing 2021 stock option incentive plan and emphasizes the management team's commitment to creating value for shareholders [3]
康弘药业: 关于2021年股票期权激励计划部分股票期权注销完成的公告